Dr Mike Dennis speaks with ecancertv at BSH 2016 about the most recent results of the multinational AML17 trial.

Using varying dosages of duanorubicin across the randomized trial, Dr Dennis reports a maximum tolerated dose of 60mg, with significant benefits to patient survival.

Most notably, he describes a specific benefit to patients with FLIP3 mutations.

He also reflects on study construction between American, English and European trials, and how to optimise techniques for best patient outcomes.

ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.